An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thromboythemia Myelofibrosis and Post Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50x109 /L to 100 x 109/L
Post Essential Thromboythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis | Primary Myelofibrosis
What is the purpose of this trial?
This clinical research study aims to find out if the drug ruxolitinib is safe and has beneficial effects in people who are diagnosed with Primary Myelofibrosis (PMF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF) or Post-Polycythemia Vera Myelofibrosis (PPV MF) and have low platelet counts (between 50 and 100 xl09/L) as a consequence of their disease (this condition is called thrombocytopenia and the patients with low platelets are referred to as thrombocytopenic).
- 18 Years and older
Click here for detailed information about who can participate in this trial.
- Incyte Corporation
- January 2012
- Last Updated:
- Study HIC#: